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Objective: Previous research indicates that pain treatment may improve sleep among
nursing home patients. We aimed to investigate the long-term effect of pain treatment
on 24-h sleep patterns in patients with comorbid depression and dementia.
Design: A 13-week, multicenter, parallel-group, double-blind, placebo-controlled
randomized clinical trial conducted between August 2014 and September 2016.
Setting: Long-term patients from 47 nursing homes in Norway.
Participants: We included 106 patients with comorbid dementia and depression
according to the Mini Mental Status Examination (MMSE) and the Cornell Scale for
Depression in Dementia (CSDD).
Intervention: Patients who were not using analgesics were randomized to receive either
paracetamol (3 g/day) or placebo tablets. Those who already received pain treatment
were randomized to buprenorphine transdermal system (maximum 10 µg/h/7 days) or
placebo transdermal patches.
Measurements: Sleep was assessed continuously for 7 days by actigraphy, at baseline
and in week 13. Total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL),
wake after sleep onset (WASO), early morning awakening (EMA), and number of wake
bouts (NoW) were evaluated. In addition, daytime total sleep time (DTS) was estimated.
Pain was assessed with Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain
Scale (MOBID-2).
Results: The linear mixed model analyses for TST, SE, SOL, WASO, EMA, NoW and
DTS showed no statistically significant differences between patients who received active
pain treatment and those who received placebo. Post hoc subgroup analyses showed
that there were no statistically significant differences between active treatment and
placebo from baseline to week 13 in patients who were in pain (MOBID-2 ≥ 3) at
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baseline, or in patients who had poor sleep (defined as SE < 85%) at baseline. Patients
who received active buprenorphine showed an increase in TST and SE compared to
those who received active paracetamol.
Conclusion: The main analyses showed that long-term pain treatment did not improve
sleep as measured with actigraphy. Compared to paracetamol, TST and SE increased
among patients who received buprenorphine. This could indicate that some patients
had beneficial effects from the most potent pain treatment. However, based on the
present findings, long-term pain treatment is not recommended as a strategy to improve
sleep. Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02267057.
Keywords: sleep, nursing home, actigraphy, pain treatment, depression, pain
INTRODUCTION
Approximately 46.8 million people worldwide suffer from
dementia – a number estimated to reach 131.5 million by
2050 (Prince et al., 2016). In nursing homes (NH), 50–80% of
patients have dementia (Helvik et al., 2015; Blytt et al., 2017b),
a neurodegenerative condition that results in the decline of
physical and cognitive functions (Cricco et al., 2001). Sleep
disturbances are common among NH patients with dementia,
with prevalence ranging from 24.5% (Moran et al., 2005) to 60%
(Neikrug and Ancoli-Israel, 2010; Ownby et al., 2014; Peter-
Derex et al., 2015). Dementia may induce pathophysiological
changes in the brain, which can interfere with the maintenance
of normal sleep (Moran et al., 2005; Neikrug and Ancoli-
Israel, 2010). Previous studies have reported that people with
dementia have more disturbed sleep than do patients without
dementia (Pat-Horenczyk et al., 1998). It is further noteworthy
that previous research indicates that NH patients with dementia
are rarely asleep or awake for a full hour in the 24-h cycle (Jacobs
et al., 1989). NH patients may suffer dramatic consequences from
sleep disturbances, for instance by increasing the risk of falls and
hip fractures (Stone et al., 2004; Morley, 2013; Widera, 2013)
and decreasing survival (Dew et al., 2003). Furthermore, sleep
disturbances contribute to impaired daytime functioning (Cricco
et al., 2001).
Several factors contribute to sleep disturbances among NH
patients, including pain (Chen et al., 2011; Flo et al., 2017)
and depression (Giron et al., 2002). Approximately 20–30% of
NH patients have depression, a disorder highly associated with
sleep disturbances (Potter and Steffens, 2007). Depression is a
common mental disorder, of which central symptoms are low
mood and low or loss of ability to experience pleasure (American
Psychiatric Association, 2013). Around 50% of the people with
Alzheimer disease experience depression during the course of
the disease (Lyketsos and Olin, 2002). Furthermore, nearly 60%
of NH patients experience pain every day (Husebo et al., 2010).
Pain is an unpleasant sensory and emotional experience (Onen
et al., 2005) and represents an important cause for poor sleep
among NH patients (Morley, 2013). Patients with dementia
may have reduced capacity to express symptoms, e.g., pain
or sleep disturbances. For this reason, it is essential that NH
staff strives to evaluate symptoms through appropriate methods.
Research suggests that pain and depression share common signal
pathways and neurotransmitters, which implies that they may be
responsive to comparable treatments. This intimate relationship
is denoted the pain-depression dyad (Chopra and Arora, 2014).
Medications such as atypical antipsychotics, benzodiazepines
and other GABAergic drugs are often sought to alleviate sleep
problems in people with dementia (McCleery et al., 2016).
However, previously conducted studies indicate that the source
of sleep problems might be changes in the brain caused by
dementia (Montplaisir et al., 1995, 1998; Kinnunen et al., 2017).
Therefore, the efficacy of treatment with various drugs in this
patient group is highly questionable (McCleery et al., 2016).
Meanwhile, a study conducted by Husebo et al. (2013) found
that a stepwise protocol for treating pain improved mood and
sleep, as measured with the Neuropsychiatric Inventory – Nursing
Home version (NPI-NH), in people with advanced dementia
and agitation. Furthermore, in a recently published randomized
controlled trial, based on the same dataset and respondents as the
present work, we found that compared to placebo, pain treatment
improved sleep after 1 week of treatment (Blytt et al., 2017a).
In the present study, we aim to investigate the long-term effect
of pain treatment on sleep in patients with comorbid dementia
and depression. In light of the results from Blytt et al. (2017a),
we hypothesized that long-term pain treatment would improve
sleep after 13 weeks in patients with comorbid dementia and
depression.
In additional post hoc subgroup analyses, we further aimed
to investigate if improvement of sleep from pain treatment
was larger in patients who were in pain at baseline, defined
as Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain
Scale (MOBID-2) score ≥ 3, than in those who were not. In
addition, we aimed to investigate the effects of pain treatment on
different sleep outcomes for patients with poor sleep at baseline,
defined as sleep efficiency (SE) < 85%. In the last analysis,
we aimed to examine if there were any differences within the
active treatment group, i.e., between patients receiving active
buprenorphine and active placebo, respectively.
MATERIALS AND METHODS
The study is based on an actigraphy subproject in the 13-week,
multicentre, parallel-group, double-blind, placebo-controlled
randomized trial “Efficacy of Pain Treatment on Depression in
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Patients with Dementia – A Randomized Clinical Trial of Efficacy:
DEP.PAIN.DEM.” The study was conducted from August 2014
to September 2016, in Norway. We included 47 NHs from 11
municipalities, located in both urban and rural areas in Norway.
In the present study, we used sleep data collected in the week
before treatment commenced (baseline) and in week 13 of the
treatment/placebo period.
Participants and Procedures
Data collection was led by two researchers who enrolled NHs
through direct contact with NH management. If the management
agreed to be part of the project, the researchers were given access
to patient medical journals to perform a pre-screening review.
If there were no recent blood analyses (electrolytes, hemoglobin,
serum creatinine, and serum alanine aminotransferase) available,
new were requisitioned. In order to be included, patients had
to be ≥60 years, long term NH patients with >4 weeks of
stay, dementia as indicated by Mini Mental State Examination
(MMSE ≤ 20) and depression as indicated by the Cornell
Scale for Depression in Dementia (CSDD ≥ 8). Patients were
excluded from the study if they had severe medical disease that
could interfere with study participation, were using any opioid
analgesic (except buprenorphine 5 mcg/h), did not want to wear
an actigraph, were immobile or had involuntary movements.
Inclusion and exclusion criteria are covered extensively in
Blytt et al. (2017a). The patient was reassessed after written
consent was given, and a drop from ≥8 to ≥6 in CSDD was
permitted between screening and baseline. In addition to all
of the inclusion and exclusion criteria, the treatment needed
to be approved by the physician responsible for the patient
(see the flow chart in Figure 1 for an overview of enrolment
and reasons for exclusion). We assessed the patients with the
same measurements at baseline and in week 13 of the treatment
period.
A stepwise protocol, with a fixed-dose regimen, for treating
pain was used in the study period (see Table 1). Patients were
allocated either to a paracetamol group or to a buprenorphine
group and randomized to receive active treatment or placebo.
If a patient showed any signs of not tolerating the treatment
(e.g., headache, dizziness or nausea), needed to change medical
treatment, or there was anything else conflicting with the patient
taking part in the study, the patient was withdrawn from the study
FIGURE 1 | Flow chart screening and inclusion (reprinted from Blytt et al., 2017a).
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1 No analgesics or
paracetamol ≤ 1g/day
Paracetamol tablets 3 g/day
Placebo tablets Inactive placebo
2 Non-opioid
analgesics/paracetamol
> 1 g/day, and/or











∗Except low-dose acetylsalicylic acid.
and the reason was recorded. During the study period, all patients
continued their usual medical treatment.
Sleep-related outcomes were measured with Actiwatch
Spectrum (Philips Respironics). Activity was assessed continuously
for 7 days at baseline and for 7 days in week 13 of the treatment
period. The intervention started on day 8. Actigraphs were
placed on the dominant/mobile wrist. As of today, there is no
standard regarding the placement of the actigraph (Camargos
et al., 2013). However, in prior studies in which sleep is evaluated
with actigraphy, the dominant arm is most commonly used
(Camargos et al., 2013). This is based on the understanding that
many NH patients may have limited mobility and therefore any
potential activity is more likely to occur in the dominant/mobile
wrist. NH staff was instructed to push the event button on the
actigraph when the patient went to bed in the evening (lights off)
and got up in the morning (lights on). These instructions were
given both verbally and in writing, and NH staff was provided
with contact information if there were any questions regarding
this procedure. The Actiware 6 (Respironics) was used for sleep
scoring. The actigraph’s sensitivity to detect motion was set to
medium. Furthermore, sleep/waking status was determined for
each one-minute epoch. A qualified technician scored all the
activity protocols. A standardized ranked approach was applied
to set rest intervals for the actigraphy data, using: event markers
when possible, light and activity data, or light or activity data.
The scoring protocol generated data on the following outcome
variables: total sleep time (TST), sleep efficiency (SE), sleep onset
latency (SOL), wake after sleep onset (WASO), early morning
awakening (EMA), and number of wake bouts (NoW). These
parameters were estimated in the time window between lights off
in the evening and lights on in the morning. In addition, daytime
total sleep time (DTS) was estimated in the time window from
lights on to lights off using the Actiware 6 software.
Pain was measured by MOBID-2 (Husebo et al., 2007),
a validated, reliable staff-administered instrument with good
responsiveness for measuring pain in people with advanced
dementia (Husebo et al., 2007, 2014). A total score ranging from
0 to 10 was set, where 10 represented the worst possible pain. The
average score was based on all of the observations during the last
week. Clinically relevant pain is defined as a score of ≥3 (Husebo
et al., 2014).
Symptoms of depression during the last week were assessed
using the validated CSDD, an instrument that consists of 19
items measuring five domains related to depression (mood,
behavioral disturbances, physical signs, cyclic functions and
ideational disturbances). In line with previous research, which
has demonstrated that a score of 8/9 complies with the diagnosis
of depression according to ICD-10 criteria, the patient had to get
a CSDD score ≥ 8 to be included in the study (Barca et al., 2010).
The CSDD score was provided using only information from NH
staff who knew the patients well.
MMSE was used to evaluate cognitive function. MMSE is a
brief, cognitive screening test with a 30-point scale that consists
of 20 tasks. It was developed to distinguish potential dementia
from normal functioning (Perneczky et al., 2006). Scores from 0
to 10 indicate severe dementia; from 11 to 20 indicate moderate
dementia; from 21 to 25 indicate mild impairment; and from 26
to 30 indicate no dementia (Perneczky et al., 2006). A score of
≤20 was necessary to be included in the study.
Initially, 162 patients were included. By means of computer-
generated random numbers, these patients were randomly
allocated to each arm in a 1:1 ratio. A statistician produced the
randomization list without any involvement from the research
team. Stratification factors were not used. However, not all
of the patients from the main study were included in the
actigraphy subproject (see the flow chart in Figure 1 for the
reasons for inclusion/exclusion). The randomization ratio in
the actigraphy subproject was therefore not 1:1. The statistician
provided the research team with a blinded, sequential list of pack
identification numbers, in which patients were consecutively
assigned to the next pack number in the list upon inclusion.
The study was double-blinded, which implied that all researchers,
patients and NH staff were masked with regard to group
allocation.
The patient’s medical decision-making capacity was
deliberated with the patient’s primary nurse. For patients
who had reduced capacity to give consent (MMSE scores from
16 to 19), attempts were made to modify the information. Also,
the researchers contacted all of the legal guardians of eligible
patients. Legal guardians who gave presumed consent on behalf
of the patient received written and oral information together
with a consent form to sign and mail back. The Regional Ethics
Committee (REC-West 2013/1474) approved the study, and the
study’s Clinical Trial number is NCT02267057.
Statistical Analyses
Descriptive statistics (means, standard deviations and
percentages) were calculated and compared across the
experimental groups both at baseline (week 0) and post-
treatment (week 13). In order to investigate the effect of pain
treatment after 13 weeks, linear mixed models were conducted.
Mixed models allow for regression-based analyses of treatment
effects even in the case of considerable attrition, as long as data
are missing at random (Bennett, 2001). Thus, individuals with
missing data at one time point can be retained in the analyses.
The mixed model for the main effect (n = 106) was conducted
Frontiers in Psychology | www.frontiersin.org 4 February 2018 | Volume 9 | Article 134
fpsyg-09-00134 February 9, 2018 Time: 20:1 # 5
Blytt et al. Sleep in Nursing Home Patients
TABLE 2 | Baseline characteristics for the different treatment groups.
Placebo
group (n = 49)
Active group
(n = 57)
Total (n = 106)
Age (mean, SD) 86.0 (6.6) 85.2 (7.8) 85.5 (7.3)
Female (%) 80 74 76
MMSE (mean, SD) 6.9 (5.8) 8.2 (6.1) 7.6 (6.0)
MOBID-2 (mean,
SD)
3.2 (2.3) 2.6 (1.9) 2.8 (2.1)
CSDD (mean, SD) 11.4 (4.1) 11.0 (3.4) 11.2 (3.7)
The table reports baseline characteristics for several central variables in the placebo
group and the active group: age, sex, mini mental status examination score
(MMSE), Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale score
(MOBID-2), Cornell Scale for Depression in Dementia score (CSDD). No statistical
significant differences were found between the groups.
with no covariates, with baseline as the time reference point,
and with random intercept. In addition, we conducted a 2 × 2
ANOVA analysis in which we included only data from the 58
patients who completed week 13. This was done to investigate if
the different analyses provided similar results.
In addition to the mixed model for the main effect, several
post hoc sub-group analyses were carried out. Linear mixed
model analyses were conducted for the sub-group of patients
with MOBID-2 score ≥ 3 (n = 46) at baseline and the
sub-group of patients with poor sleep at baseline, defined as
sleep efficiency < 85% (Lacks and Morin, 1992) (n = 90).
Finally, linear mixed model analyses were conducted to compare
patients receiving active paracetamol and active buprenorphine
treatment, respectively (n = 57). The statistical analyses were
conducted using IBM SPSS Statistics 24.
RESULTS
Two thousand three hundred and twenty three patients were
screened for potential inclusion and 106 patients were included
in the actigraphy subproject (see flow chart in Figure 1).
Mean age was 85.5 years and 76% of the patients were
female. Mean scores for MMSE, MOBID-2 and CSDD were
7.6, 2.8, and 11.2, respectively (see Table 2). From baseline
to week 13, 48 patients dropped out of the study (reasons
for dropout are listed in Table 3). There were no statistically
significant differences in relevant baseline characteristics (age,
sex, CSDD, MOBID-2, NPI-NH, MMSE) between the patients
who dropped out (n = 48) and the patients who completed
treatment through week 13 (n = 58) (see Table 4). This supports
the assumption that the data were missing at random. Nine
patients were using buprenorphine 5 µg/h prior to inclusion and
stayed on this treatment and were then randomized to receive
either an additional 5 µg/h (5 patients) or placebo patch (4
patients).
The main linear mixed model analyses for sleep outcomes
showed no statistically significant differences between patients
who received active pain treatment compared to those who
received placebo (see Table 5). Similarly, in the 2 × 2 ANOVA
TABLE 4 | Comparison of baseline characteristics for patients who completed the






Total (n = 106)
Age (mean, SD) 84.5 (7.1) 86.8 (7.3) 85.5 (7.3)
Female (%) 78 75 76
MMSE (mean, SD) 7.1 (5.7) 8.3 (6.3) 7.6 (6.0)
MOBID-2 (mean,
SD)
2.8 (2.0) 2.8 (2.3) 2.8 (2.1)
CSDD (mean, SD) 11.4 (3.8) 10.9 (3.7) 11.2 (3.7)
The table reports baseline characteristics for several central variables in the group
of patients who completed the study period and those who dropped out; age, sex,
MMSE, Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale score
(MOBID-2), Cornell Scale for Depression in Dementia score (CSDD). No statistical
significant differences were found between the groups.
TABLE 3 | Overview of dropout (n = 48) in week 13.
Placebo











Gastrointestinal 0 0 0 4 4
Neurological 0 0 0 2 2
Psychological 0 2 0 6 8
Infection 0 0 1 0 1





1 7 8 6 22
Patient refused to
take the medication
0 3 0 0 3
Change in
treatment
0 0 1 0 1
Death 0 0 1 2 3
The table reports reasons for dropout in each of the four experimental groups: active/placebo paracetamol/buprenorphine.
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analyses with only the 58 patients who had complete data in
week 13, there were no significant differences between active pain
treatment and placebo. Table 5 also shows descriptive statistics
of sleep characteristics for both the placebo group and the active
group, as measured at baseline and in week 13 of the treatment
period.
Table 6 reports analyses for the subgroup of patients
with pain (MOBID-2 score ≥ 3) at baseline. There were no
statistically significant differences between the patients who
received active treatment and those who received placebo.
Table 7 shows analyses for the subgroup of patients with sleep
efficiency < 85% at baseline. Again, there were no statistically
significant differences between the patients who received active
treatment and those who received placebo.
Table 8 reports analyses for the subgroup of patients
receiving the two different types of active pain treatment –
paracetamol and buprenorphine, respectively. In this linear
mixed model, there were significant effects on TST (p < 0.01)
and SE (p < 0.05), which revealed that TST and SE were
both improved after 13 weeks for patients who received active
buprenorphine compared with patients who received active
paracetamol.
DISCUSSION
This is the first placebo-controlled trial to investigate the long-
term efficacy of paracetamol and buprenorphine on sleep in
patients with comorbid dementia and depression. Previous
studies have found that depression among NH patients with
dementia may be related to untreated pain (Leong and Nuo,
2007). Moreover, it is well established that pain is associated
with sleep disturbances (Chen et al., 2011; Flo et al., 2017).
Based on our findings in Blytt et al. (2017a) that pain treatment
improved sleep in NH patients with comorbid dementia and
depression after one week of pain treatment, we hypothesized
that pain treatment would continue to improve sleep after
13 weeks in this patient group. Contrary to our hypothesis,
the main mixed model analyses for the full sample showed no
statistically significant differences between active and placebo
treatment.
There were, however, interesting significant effects in one
of the post hoc sub-group analyses: TST improved for patients
who received active buprenorphine, compared to those who
received active paracetamol. In the active paracetamol group,
TST was reduced by about 10 min, while it increased by
more than one hour in the active buprenorphine group.
Furthermore, we found that SE was reduced in the group
who received active paracetamol, while it increased by about
9% in the group who received active buprenorphine. Thus,
patients who received active buprenorphine seemed to benefit
from the treatment. These results are in line with Blytt et al.
(2017a), wherein we also found that the group of patients
who received active buprenorphine had significantly improved
TST compared to the active paracetamol group after one
week of treatment. However, the underlying mechanisms are
unclear.
Sedation is a frequently reported opioid-associated side
effect (McNicol et al., 2003). Usually, symptoms of sedation
decline after a few days in more healthy adults. However,
among people with comorbidity, sedation may persist (McNicol
et al., 2003). In Blytt et al. (2017a), we highlight that the
positive effect on TST after one week of treatment could be
attributed to such a side-effect. There is a lack of studies
that investigate how symptoms of sedation may persist among
older people with comorbidity, and we cannot exclude sedation
TABLE 5 | Linear mixed model analyses investigating the long-term effect of pain treatment on sleep outcomes (n = 106).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −2.52 515.2 (139.3) – 538.5 (142.4) 509.9 (113.6) – 498.3 (146.8)
p 0.90
SE (%) C −0.78 70.0 (15.0) – 73.0 (15.3) 70.0 (13.1) – 68.5 (18.2)
p 0.76
SOL (min) C 5.68 33.0 (37.3) – 31.3 (43.0) 47.0 (44.5) – 52.2 (63.5)
p 0.61
WASO (min) C −7.27 134.5 (66.4) – 116.9 (51.7) 140.6 (68.3) – 133.7 (69.8)
p 0.58
EMA (min) C 11.73 48.9 (60.4) – 44.4 (54.9) 30.7 (38.9) – 42.8 (45.5)
p 0.22
NoW (no) C −0.38 30.3 (12.5) – 28.1 (11.5) 31.2 (11.6) – 30.7 (11.0)
p 0.90
DTS (min) C 26.27 191.7 (124.0) – 206.2 (130.3) 215.8 (104.2) – 254.5 (106.5)
p 0.15
The table reports linear mixed model analyses for the following outcome variables: TST, total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, wake after
sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time. The column “Treatment effect” reports the interaction effect
between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point. C refers to coefficients and p refers to p-values. The column
“Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from baseline to week 13, with standard deviations in parentheses.
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TABLE 6 | Linear mixed model analyses for the subgroup of patients with pain (MOBID-2 score ≥ 3) at baseline (n = 46).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −9.71 563.5 (139.1) – 635.1 (152.2) 517.8 (122.2) – 500.8 (151.8)
p 0.80
SE (%) C −1.17 75.2 (14.4) – 80.4 (16.0) 70.5 (14.4) – 67.9 (18.4)
p 0.77
SOL (min) C 7.85 23.5 (25.8) – 17.7 (32.7) 40.5 (43.6) – 49.0 (55.2)
p 0.50
WASO (min) C 1.12 124.3 (71.2) – 91.7 (61.4) 138.7 (65.5) – 142.1 (73.0)
p 0.97
EMA (min) C −1.02 32.2 (35.2) – 43.5 (60.0) 36.6 (49.6) – 43.4 (51.6)
p 0.95
NoW (no) C 2.03 32.2 (15.8) – 25.3 (16.0) 32.8 (15.2) – 32.5 (13.8)
p 0.75
DTS (min) C 28.33 251.3 (140.3) – 253.4 (126.5) 226.8 (114.6) – 254.5 (101.6)
p 0.39
The table reports linear mixed model analyses for the subgroup of patients with pain (MOBID-2 score ≥ 3) for the following outcome variables: TST, total sleep time; SE,
sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time.
The column “Treatment effect” reports the interaction effect between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point.
C refers to coefficients and p refers to p-values. The column “Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from
baseline to week 13, with standard deviations in parentheses.
TABLE 7 | Linear mixed model analysis for the subgroup of patients with poor sleep (sleep efficiency < 85%) at baseline (n = 90).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −4.81 477.1 (116.7) – 463.2 (104.9) 490.2 (95.3) – 470.4 (130.3)
p 0.85
SE (%) C −1.54 65.5 (12.5) – 65.7 (13.6) 67.7 (11.0) – 65.2 (16.9)
p 0.64
SOL (min) C −0.24 38.7 (38.7) – 45.7 (47.5) 50.1 (43.6) – 58.5 (65.0)
p 0.99
WASO (min) C 3.93 153.0 (57.5) – 136.4 (40.2) 151.3 (62.5) – 147.1 (64.3)
p 0.81
EMA (min) C 14.11 56.8 (63.6) – 57.7 (64.1) 33.3 (36.8) – 46.8 (46.8)
p 0.27
NoW (no) C −1.58 32.7 (11.1) – 32.0 (10.0) 32.7 (11.1) – 32.0 (12.1)
p 0.61
DTS (min) C 7.74 161.6 – 167.5 (105.7 – 110.4) 205.2 (98.9) – 240.5 (110.7)
p 0.72
The table reports linear mixed model analyses for the subgroup of patients with sleep efficiency < 85% for the following outcome variables: TST, total sleep time; SE,
sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time.
The column “Treatment effect” reports the interaction effect between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point.
C refers to coefficients and p refers to p-values. The column “Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from
baseline to week 13, with standard deviations in parentheses.
as a potential explanation of the results from the present
study.
Importantly, we found no clear causal effect on the active
group with clinically significant pain (MOBID-2 score ≥ 3),
compared to placebo. This is contrary to previous studies on older
people, in which sleep disturbances have been linked to untreated
pain (Chen et al., 2011). In addition, pain has previously been
shown to reduce SE and to increase WASO and stage 1 sleep at
the expense of slow wave sleep and REM sleep (Onen et al., 2005).
It is, however, noteworthy that in the subgroup analysis including
patients with clinically significant pain, all of the sleep parameters
(except EMA) showed indication of improvement, compared
to placebo. However, no statistically significant differences were
found. This could, however, be attributed to the low number of
patients with pain at baseline (n = 46), and we cannot exclude
type 2 errors.
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TABLE 8 | Linear mixed model analysis for the subgroup of patients receiving the two different types of active pain treatment – paracetamol and buprenorphine (n = 57).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Paracetamol Buprenorphine
TST (min) C 68.56 522.9 (149.1) – 511.4 (141.9) 508.7 (132.6) – 580.6 (140.7)
p 0.01
SE (%) C 7.32 71.4 (14.4) – 70.2 (15.0) 68.7 (15.7) – 77.4 (15.8)
p 0.03
SOL (min) C −20.66 37.9 (40.0) – 41.4 (48.4) 29.0 (35.0) – 15.6 (28.8)
p 0.14
WASO (min) C −14.91 121.6 (62.5) – 118.8 (38.4) 145.3 (68.7) – 113.9 (70.3)
p 0.54
EMA (min) C −19.93 42.1 (46.7) – 48.2 (57.2) 54.7 (70.1) – 38.5 (54.0)
p 0.26
NoW (no) C −10.17 28.0 (11.7) – 30.8 (8.24) 32.2 (13.0) – 23.7 (14.7)
p 0.07
DTS (min) C 44.04 173.2 (127.0) – 167.1 (124.6) 207.2 (121.3) – 267.0 (120.9)
p 0.10
The table reports linear mixed model analyses for the subgroup of patients receiving active paracetamol and active buprenorphine, respectively, for the following outcome
variables: TST, total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; Now, number of wake
bouts; DTS, daytime total sleep time. The column “Treatment effect” reports the interaction effect between type of treatment and time, i.e., the main result of the clinical
trial, with baseline as the reference time point. C refers to coefficients and p refers to p-values. P-values printed in bold denote statistical significance. The column “Pre-post
sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from baseline to week 13, with standard deviations in parentheses.
Limitations and Strengths
Due to the considerable attrition of patients at week 13, we
conducted linear mixed model analyses. These analyses are
appropriate to handle missing data and can take into account the
dependency of the observations (Bennett, 2001).
There was a drop-out of 22 patients in the group who received
active buprenorphine, suggesting that many patients did not
tolerate such treatment (see Table 3). This large drop-out may
have hindered our ability to detect a positive effect from the active
treatment compared to placebo. Furthermore, it should be noted
that the assignment to paracetamol or buprenorphine was not
a result of randomization, but of whether the patients qualified
for allocation to either paracetamol or buprenorphine at baseline
(and then were randomized to either active or placebo treatment).
This may produce bias by indication, since the choice of drug
might be related to the outcome.
In addition, during the last decade, there has been a change
in the prescription of pain medication for NH patients. Sandvik
et al. (2016) found that the use of paracetamol and strong opioids
increased significantly from 2000 to 2011. This affected the
inclusion of patients, since patients already taking opioids could
not be included in the study. Prior to inclusion, nine patients
were using buprenorphine, of which five patients received active
treatment and four patients received placebo treatment. This is
not a source of bias since the comparison was between baseline
data (pre-treatment) and week 13 (post-treatment). Therefore,
any potential effects measured in week 13 will be additional effects
of the treatment. However, the large drop-out in combination
with the difficulty to recruit patients to the study is a threat to
the generalizability of the study and we cannot exclude selection
bias.
Measuring sleep with actigraphy has its limitations.
Actigraphy only records movement, and a lack of movement
would therefore be assessed as sleep. The study population
had low SE, and previous studies show that actigraphy
is less accurate in distinguishing sleep from wakefulness
when SE is reduced (Sivertsen et al., 2006). Actigraphy
recordings may therefore overestimate sleep relative to
sleep diaries (Kushida et al., 2001; Sivertsen et al., 2006).
It is therefore recommended that clinicians use sleep
diaries/logs in addition to actigraphy, when evaluating sleep
in NH patients. This would have strengthened the study
design.
An additional limitation of the study was that we did not
conduct a priori power analyses. The lack of this renders us
unable to assess whether the statistical analyses had sufficient
power. It is, however, noteworthy that our sample of patients
with actigraphy was similar or larger than samples in comparable
studies (Fetveit and Bjorvatn, 2005; Dowling et al., 2008;
Camargos et al., 2014).
Compared to placebo, pain treatment did not improve sleep
in the full sample of patients, as measured with actigraphy.
However, we found a significant effect on TST and SE, when
we compared the different types of active pain treatment.
These results indicate that some patients may experience
beneficial effects of pain treatment. However, the underlying
mechanisms are unclear. The results could be an indication
that some of the patients in fact experience pain, and
hence had a positive effect of more potent pain treatment.
Future research should investigate this further, with a larger
sample size and including patients with clinically significant
pain.
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